Jonathan Young Net Worth

The estimated Net Worth of Jonathan Young is at least $11.2 Milion dollars as of 3 September 2024. Jonathan Young owns over 5,000 units of Akero Therapeutics Inc stock worth over $6,068,199 and over the last 5 years he sold AKRO stock worth over $2,998,382. In addition, he makes $2,133,660 as Co-Founder, Chief Operating Officer a Executive Vice President at Akero Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Jonathan Young AKRO stock SEC Form 4 insiders trading

Jonathan has made over 31 trades of the Akero Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 5,000 units of AKRO stock worth $133,600 on 3 September 2024.

The largest trade he's ever made was exercising 83,321 units of Akero Therapeutics Inc stock on 1 March 2024 worth over $51,659. On average, Jonathan trades about 8,510 units every 42 days since 2019. As of 3 September 2024 he still owns at least 236,854 units of Akero Therapeutics Inc stock.

You can see the complete history of Jonathan Young stock trades at the bottom of the page.

Jonathan Young biography

Dr. Jonathan Young J.D., Ph.D. serves as Co-Founder, Chief Operating Officer, Executive Vice President of the Company. Dr. Young served as our co-founder, President and Chief Executive Officer from April 2017 to September 2018, and since September 2018 as our co-founder, Executive Vice President and Chief Operating Officer. Before joining the Company, Dr. Young served as a Venture Partner at Apple Tree Partners, a venture capital firm, from October 2016 to September 2018. From August 2014 to October 2016, he served as Vice President of Policy/Advocacy and General Counsel at Braeburn Pharmaceuticals, Inc. From October 2006 through August 2014, Dr. Young served in positions of increasing responsibility at FoxKiser LLP, a legal services firm, ultimately as Partner and General Counsel. Dr. Young holds a B.A. in history from Messiah College, an M.A. and Ph.D. in American history from the University of North Carolina at Chapel Hill and a J.D. from Yale Law School.

What is the salary of Jonathan Young?

As the Co-Founder, Chief Operating Officer a Executive Vice President of Akero Therapeutics Inc, the total compensation of Jonathan Young at Akero Therapeutics Inc is $2,133,660. There are 2 executives at Akero Therapeutics Inc getting paid more, with Andrew Cheng having the highest compensation of $5,431,810.

How old is Jonathan Young?

Jonathan Young is 50, he's been the Co-Founder, Chief Operating Officer a Executive Vice President of Akero Therapeutics Inc since 2018. There are 8 older and 6 younger executives at Akero Therapeutics Inc. The oldest executive at Akero Therapeutics Inc is Dr. Timothy Rolph, 67, who is the Co-Founder & Chief Scientific Officer.

What's Jonathan Young's mailing address?

Jonathan's mailing address filed with the SEC is C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA, 94941.

Insiders trading at Akero Therapeutics Inc

Over the last 5 years, insiders at Akero Therapeutics Inc have traded over $146,260,704 worth of Akero Therapeutics Inc stock and bought 4,870,000 units worth $104,250,550 . The most active insiders traders include Group, Llc Green Jeremy Red..., Trust Blue Horizon Enterpri... a G. Walmsley Graham. On average, Akero Therapeutics Inc executives and independent directors trade stock every 11 days with the average trade being worth of $1,642,344. The most recent stock trade was executed by Jonathan Young on 3 September 2024, trading 5,000 units of AKRO stock currently worth $133,600.

What does Akero Therapeutics Inc do?

akero therapeutics is developing best-in-class medicines that restore metabolic balance to treat non-alcoholic steatohepatitis (nash) and other serious metabolic diseases. akero's lead clinical program, akr-001, is a long-acting fc fusion modified fgf21 protein and potential best-in-class treatment for nash. akr-001 builds upon two decades of work on fgf21 biology. it is designed to affect both the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis.

Complete history of Jonathan Young stock trades at Akero Therapeutics Inc

Akero Therapeutics Inc executives and stock owners

Akero Therapeutics Inc executives and other stock owners filed with the SEC include:

• Andrew Cheng,
  President, Chief Executive Officer, Director
• William White,
  Chief Financial Officer, Executive Vice President and Head of Corporate Development
• Timothy Rolph,
  Co-Founder, Chief Scientific Officer
• Jonathan Young,
  Co-Founder, Chief Operating Officer, Executive Vice President
• Dr. Andrew Cheng,
  Pres, CEO & Director
• Dr. Timothy Rolph,
  Co-Founder & Chief Scientific Officer
• Dr. Jonathan M. Young,
  Co-Founder, Exec. VP, COO & Sec.
• William R. White J.D.,
  Exec. VP, CFO, Treasurer & Head of Corp. Devel.
• Mark Iwicki,
  Independent Non-Executive Chairman of the Board
• Kevin Bitterman,
  Non-Executive Independent Director
• Seth Harrison,
  Non-Executive Independent Director
• Graham Walmsley,
  Non-Executive Independent Director
• Kitty Yale,
  Chief Development Officer
• Jane Henderson,
  Non-Executive Independent Director
• Tomas Heyman,
  Independent Director
• Kitty Yale,
  Exec. VP & Chief Devel. Officer
• John J. Schembri,
  VP of Fin. & Controller
• Venture Fund Xi, L.P. Atlas,
  10% owner
• Trust Blue Horizon Enterpri...,
  
• Venture Capital Vi, L.P.Ver...,
  
• Group, Llc Green Jeremy Red...,
  
• Global Strategic Fund Ii L....,
  
• Venture Fund Xi, L.P.Atlas ...,
  
• Aaron Royston,
  Director
• Venture Capital Vi, L.P. Ve...,
  10% owner
• Life Science Ventures, L.P....,
  
• Venture Fund Xi, L.P.Atlas ...,
  
• Venture Opportunity Fund I,...,
  10% owner
• Chou Judy,
  
• Catriona Yale,
  Chief Development Officer
• Yuan Xu,
  
• Scott A. Gangloff,
  Chief Technology Officer
• Patrick Lamy,
  Senior VP, Commercial Strategy